The costs of epilepsy in Italy: A prospective cost-of-illness study in referral patients with disease of different severity

Epilepsy Research

Volumn 48, Issue 3, 2002, Pages 207-216

  Tetto, A ^a   Manzoni, P ^a   Millul, A ^a   Beghi, Ettore ^a,b   Garattini, L ^b   Tartara, A ^c   Avanzini, G ^d  

^a SAN GERARDO HOSPITAL   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^d DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Costs; Diagnosis; Epilepsy; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; PHENOBARBITAL; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; ELECTROENCEPHALOGRAPHY; EPILEPSY; FEMALE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEALTH CARE COST; HOSPITAL COST; HOSPITAL SERVICE; HOSPITALIZATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PATIENT REFERRAL; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; EPILEPSY; FEMALE; HUMANS; INFANT; ITALY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REFERRAL AND CONSULTATION; SEVERITY OF ILLNESS INDEX;

EID: 18344363894     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(02)00013-X     Document Type: Article

References (27)

1. The prevalence and direct costs of epilepsy in Australia
2. Opinioni e prassi correnti sulla terapia delle epilessie: Intervista postale di un campione di clinici Italiani
3. Antiepileptic drugs as 'tracers' of disease. A calculation of the prevalence of epilepsy through an analysis of drug consumption
4. Cost of epilepsy in the United States: A model based on incidence and prognosis
5. Methodological issues in estimating the cost of epilepsy
6. Direct medical costs of refractory epilepsy incurred by three different treatment modalities, a prospective assessment
7. The cost of epilepsy in the United Kingdom: An estimation based on the results of two population-based studies
8. Pharmacoeconomic considerations in the drug treatment of epilepsy
9. Prognosis of epilepsy: A review and further analysis of the first 9 years of the British National General Practice Study of Epilepsy. A prospective population-based study
10. Economic cost of epilepsy
11. Guidelines for epidemiological studies on epilepsy
12. ILAE commission report. Epilepsy in the Tropics: II. Clinical presentations, pathophysiology, immunologic diagnosis, economics, and therapy
13. The cost of epilepsy in Switzerland
14. Payer costs of patients diagnosed with epilepsy
15. Prevalence of epilepsy in Minnesota, 1940-1980
16. Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries
17. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy
18. Uptake and costs of care for epilepsy: Findings from a UK regional study
19. Cost analysis of epilepsy surgery and of vigabatrin treatment in patients with refractory partial epilepsy
20. Norms of care in British and American neurologic practice
21. Cost of refractory epilepsy in adults in the USA
22. ILAE classification of epilepsies: Its applicability and practical value of different diagnostic categories
23. The contribution of tertiary centers to the quality of the diagnosis and treatment of epilepsy
24. Incidence and prevalence studies of epilepsy and their methodological problems: A review
25. The delivery and cost of medical services for people with epilepsy
26. Relationship between seizure frequency and costs and quality of life of outpatients with partial epilepsy in France, Germany and the United Kingdom